A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers

Pharmazie

Volumn 64, Issue 2, 2009, Pages 71-75

  Rhim, Si Youn ^a   Park, Jin Hee ^a   Park, Yoo Sin ^a   Kim, Dong Sun ^a   Lee, Min Ho ^a   Shaw, Leslie M ^b   Kang, Ju Seop ^a  

^a Hanyang University   (South Korea)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLEBOPRIDE; CTITRAZOLE; ITRACONAZOLE; TERT BUTYL METHYL ETHER; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KOREA; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRECIPITATION; SENSITIVITY AND SPECIFICITY; SEPARATION TECHNIQUE; TANDEM MASS SPECTROMETRY; BLOOD; CALIBRATION; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; MICROCAPSULE; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; STANDARD;

ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CALIBRATION; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; HUMANS; INDICATORS AND REAGENTS; ITRACONAZOLE; MALE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 65349097331     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.7795     Document Type: Article

References (26)

1. Ackermann B, Berna Mj, Murphy A (2002) Recent advances in use of LC/MS/MS for quantitative high-throughput bioanalytical support of drug discovery. Curr Top Med Chem 2: 53-66.
2. Al-Rawithi S, Hussein R, Al-Moshen I, Raines D (2001) Expedient microdetermination of itraconazole and hydroxyitraconazole in plasma by high-performance liquid chromatography with fluorescence detection. Ther Drug Monitor 23: 445-448.
3. Barone J, Moskovitz B, Guarnieri J, Hassell A, Colaizzi J, Bierman R, Jessen L (1998) Enhanced bioavailability of itraconazole in hydroxypropyl-beta- cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 42: 1862-1865.
4. Carrier A, Parent J (2000) Liquid chromatographic-mass spectrometric determination of itraconazole and its major metabolite, hydroxyitraconazole, in dog plasma. J Chromatogr B Biomed Sci Appl 745: 413-420.
5. Chen Ml, Shah V, Patnaik R, Adams W, Hussain A, Conner D, Mehta M, Malinowski H, Lazor J, Huang Sm, Hare D, Lesko L, Sporn D, Williams R (2001) Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res 18: 1645-1650.
6. Conway S, Etherington C, Peckham D, Brownlee K, Whitehead A, Cunliffe H (2004) Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. J Antimicrob Chemother 53: 841-847.
7. Guidance for industry (2001) Statistical approaches to establishing bioequivalence. USDHHS, FDA, CDER, CVM
8. Gubbins P, Gurley B, Bowman J (1998) Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum. Journal of pharmaceutical and biomedical analysis 16: 1005-1012.
9. Hardin T, Graybill J, Fetchick R, Woestenborghs R, Rinaldi M, Kuhn J (1988) Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 32: 1310-1313.
10. Hyder A (2001) Revised declaration of Helsinki. Ethics is not just for ethicists. BMJ Clinical research ed. 323: 283; author reply 284.
11. Jemal M (2000) High-throughput quantitative bioanalysis by LC/MS/MS. Biomed Chromatogr 14: 422-429.
12. Kauffman C (1996) Role of azoles in antifungal therapy. Clin Infect Dis 22 Suppl 2: S148-153.
13. Koks C, Sparidans R, Lucassen G, Crommentuyn K, Beijnen J (2002) Selective high-performance liquid chromatographic assay for itraconazole and hydroxyitraconazole in plasma from human immunodeficiency virus-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci 767: 103-110.
14. Kousoulos C, Tsatsou G, Apostolou C, Dotsikas Y, Loukas Y (2006) Development of a high-throughput method for the determination of itraconazole and its hydroxy metabolite in human plasma, employing automated liquid-liquid extraction based on 96-well format plates and LC/ MS/MS. Anal Bioanal Chem 384: 199-207.
15. Lohitnavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W (2005) Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther 30: 201-206.
16. Lyman C, Walsh T (1992) Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44: 9-35.
17. Srivatsan V, Dasgupta A, Kale P, Datla R, Soni D, Patel M, Patel R, Mavadhiya C (2004) Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by high-performance liquid chromatography. J Chromatogr 1031: 307-313.
18. Suarez-Kurtz G, Bozza F, Vicente F, Ponte C, Struchiner C (1999) Limited-sampling strategy models for itraconazole and hydroxy-itraconazole based on data from a bioequivalence study. Antimicrob Agents Chemother 43: 134-140.
19. Uno T, Shimizu M, Sugawaeak, Tateishi T (2006) Sensitive determination of itraconazole and its active metabolite in human plasma by columnswiching high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 28: 526-531.
20. Vogeser M, Spohrer U, Schiel X (2003) Determination of itraconazole and hydroxyitraconazole in plasma by use of liquid chromatography-tandem mass spectrometry with on-line solid-phase extraction. Clin Chem Lab Med 41: 915-920.
21. Warnock D, Turner A, Burke J (1988) Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. J Antimicrob Chemother 21: 93-100.
22. Wong J, Nisar U, Yuen K (2003) Liquid chromatographic method for the determination of plasma itraconazole and its metabolite in pharmacokinetic/ bioavailability studies. J Cromatogr B 798: 355-360.
23. Xu R, Fan L, Rieser M, El-Shourbagy T (2007) Recent advances in highthroughput quantitative bioanalysis by LC-MS/MS. J Pharm Biomed Anal 44: 342-355.
24. Yao M, Chen L, Srinivas NR (2001) Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 752: 9-16.
25. Yeates R, Zimmermann T, Laufen H, Albrecht M, Wildfeuer A (1995) Comparative pharmacokinetics of fluconazole and of itraconazole in Japanese and in German subjects. Int J Clin Pharmacol Therap 33: 131-135.
26. Yun H, Baek M, Park I, Choi B, Kwon K (2006) Comparative analysis of the effects of rice and bread meals on bioavailability of itraconazole using NONMEM in healthy volunteers. Eur J Clin Pharmacol 62: 1033-1039.